KHK6640

Kyowa Kirin Co., Ltd. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	KHK6640
Sponsor	Kyowa Kirin Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease (PHASE1)
A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease (PHASE1)
A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KHK6640 CI brief — competitive landscape report
KHK6640 updates RSS · CI watch RSS
Kyowa Kirin Co., Ltd. portfolio CI